Table 2 Discounted costs, discounted quality-adjusted life expectancy (QALYs), and incremental cost-effectiveness ratios (ICERs) for the base-case analysis (screening every 3 years)

From: Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening

Strategy

(Sensitivity, specificity)

Cost ($)

Incr. cost ($)

Eff. (QALYs)

Incr. eff. (QALYs)

ICER ($/QALY)

Notes

No screening

 

$189

 

24.685

   

Ploidy 5 cell

(0.51; 0.95)

$763

$574

24.715

0.030

$18 821

Extended dominance

Ploidy 4 cell

(0.55; 0.95)

$767

$577

24.716

0.032

$18 264

a

Ploidy 3 cell

(0.59; 0.93)

$878

$110

24.717

0.001

$132 803

 

Ploidy 2 cell

(0.65; 0.90)

$1044

$167

24.718

0.001

$148 863

 

Ploidy 1 cell

(0.74; 0.82)

$1482

$438

24.719

0.001

$418 436

Extended dominance

Papanicolaou smear

(0.84; 0.88)

$1758

$276

24.722

0.004

$192 502

b

  1. Abbreviations: Eff= effectiveness; Incr= incremental.
  2. aWas compared with the no screening strategy because the ploidy 5 cell strategy was dominated in an extended sense.
  3. bWas compared with the ploidy 2 cell strategy because the ploidy 1 cell strategy was dominated in an extended sense.